Recombinant haemoglobin 3011

Drug Profile

Recombinant haemoglobin 3011

Alternative Names: Recombinant haemoglobin 3011 - Baxter Healthcare; rHb3011

Latest Information Update: 02 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter Healthcare Corporation
  • Class Plasma expanders
  • Mechanism of Action Haemoglobin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypovolaemia

Most Recent Events

  • 31 Dec 2003 Discontinued - Phase-I for Hypovolaemia in USA (Parenteral)
  • 03 Dec 2003 Phase-I clinical trials in Hypovolaemia in USA (Parenteral)
  • 06 Dec 2001 No-Development-Reported for Hypovolaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top